i-Pharm
  • More

    Featured

    GxP Insights
    GxP Insights: 2025 in Review: The Surge in US-Based Life Sciences Manufacturing

    Welcome to our monthly industry insights newsletter, tailored for professionals in Medical D...

    By David Dolman 18 December, 2025

    i-Pharm News
    i-Pharm Consulting Group Announces Transition to Employee Ownership Trust

    i-Pharm Consulting Group has taken the next major step in its evolution by transitioning to ...

    By i-Pharm Consulting 08 December, 2025

    i-Pharm News
    ExSight Ventures & i-Pharm Consulting Announce Strategic Talent Partnership Across Ophthalmology Portfolio

    i-Pharm to deliver top executive and board talent for the ExSight portfolio.    &n...

    By Hannah Roberts 28 July, 2025

    Case Study
    Case Study: Global VP Regulatory Affairs, Australian Medical Devices Company 03 July, 2023

    By i-Pharm Consulting 03 July, 2023

    Industry Insights
    Clinical Operations: What It Is and Why It’s Important 01 June, 2023

    By i-Pharm Consulting 01 June, 2023

    GxP Insights
    GxP Insights: FDA Form 483s: What the Surge in Enforcement Means for U.S. Drug Manufacturers

    Welcome to our monthly industry insights newsletter, tailored for professionals in Medical D...

    By David Dolman08 June, 2026

    GxP Insights
    GxP Insights: The Purolea Warning Letter: What It Means for AI in GxP Manufacturing

    By David Dolman05 May, 2026

    GxP Insights
    GxP Insights: US Life Sciences Manufacturing: The New Hubs Taking Shape.

    By David Dolman07 April, 2026

    GxP Insights
    GxP Insights: FDA PreCheck Pilot Goes Live: A New Era for Domestic Manufacturing Oversight?

    By David Dolman05 March, 2026

    GPTW Certified UK 22-23
    GPTW Certified ANZ 22-23
    GPTW Certified USA 22-23
    Best Workplaces
    Wellbeing
    GPTW Best Work Places for Women 2022
    SIA
    Kelly Supplier Excellence Award 2022
    © i-Pharm 2023
    Site by Venn